Is it REALLY asthma?
Clinical studies indicate that up to 33% of patients with an asthma diagnosis did not have asthma when objectively assessed.1
ARIDOL® (mannitol) is indicated for the assessment of bronchial hyperresponsiveness (BHR) in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma. BHR is a key clinical feature of respiratory conditions such as exercise-induced bronchoconstriction and asthma.3
The right diagnosis is critical
Common symptoms of asthma are cough, wheeze, and shortness of breath. But there are other respiratory illnesses with similar symptoms. Some of them include:
It is important to correctly diagnose patients with symptoms of asthma. Patients that are on a treatment plan for asthma but who do not experience an improvement in their symptoms may not have asthma. Bronchial challenge tests with Provocholine® (methacholine chloride) and Aridol® (mannitol) can help to find the right diagnosis.
The right diagnosis is critical for an effective treatment plan to improve quality of life, whether patients have asthma or a different condition with similar respiratory symptoms.
Learn more about bronchial challenge tests
Connect with a Clinical Specialist to schedule your complimentary Education Session (CRCE credit options)
Please enter your name and email below.
Focused on every breath
Methapharm Respiratory supports clinicians in the diagnostic process with methacholine and mannitol challenge tests as objective measures of airway hyperresponsiveness.
We also offer training and education (CRCE) at no cost.
Provocholine® (methacholine chloride)
INDICATION: Provocholine is indicated for the diagnosis of bronchial airway hyperreactivity in adults and pediatric patients 5 years of age and older who do not have clinically apparent asthma.
WARNING: SEVERE BRONCHOCONSTRICTION
WARNING: SEVERE BRONCHOCONSTRICTION Severe bronchoconstriction can result from Provocholine administration (including the lowest dose). The use of Provocholine is contraindicated in pediatric and adult patients with baseline FEV1 < 60% predicted or adults with FEV1 < 1.5 L. Because of the potential for severe bronchoconstriction, the use of Provocholine in patients with clinically apparent asthma or wheezing is not recommended. Emergency equipment and medication should be immediately available to treat acute respiratory distress. If severe bronchoconstriction occurs, reverse immediately with a rapid-acting inhaled bronchodilator agent (β-agonist). If baseline spirometry is not performed or is measured inaccurately, the initial FEV1 may be underestimated. In this situation, decreases in FEV1 may not be detected after administration of escalating Provocholine doses, which may result in administration of unnecessary higher doses and an increased risk for excessive bronchoconstriction [see Warnings and Precautions – Section 5.1 of the Prescribing Information].
Aridol® (mannitol inhalation powder)
INDICATION: ARIDOL is a sugar alcohol indicated for the assessment of bronchial hyperresponsiveness in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma.
WARNING: RISK OF SEVERE BRONCHOSPASM
Mannitol, the active ingredient in ARIDOL, acts as a bronchoconstrictor and may cause severe bronchospasm. Bronchial challenge testing with ARIDOL is for diagnostic purposes only. Bronchial challenge testing with ARIDOL should only be conducted by trained professionals under the supervision of a physician familiar with all aspects of the bronchial challenge test and the management of acute bronchospasm. Medications (such as short-acting inhaled beta-agonist) and equipment to treat severe bronchospasm must be present in the testing area. If severe bronchospasm occurs it should be treated immediately by administration of a shortacting inhaled beta-agonist. Because of the potential for severe bronchoconstriction, the bronchial challenge testing with ARIDOL should not be performed in any patient with clinically apparent asthma or very low baseline pulmonary function tests (e.g., FEV1<1-1.5 liters or <70% of the predicted values) [see Warnings and Precautions (5.1) of the Prescribing Information].
- Aaron SD, Vandemheen KL, et al. Reevaluation of Diagnosis in Adults with Physician-Diagnosed Asthma. JAMA. 2017 Jan 17;317(3):269-279.
- Provocholine package insert, revised 11/2020.
- Aridol package insert, revised 08/2021.
Provocholine® is a registered trademark of Methapharm Inc. Aridol® is a registered trademark of Pharmaxis Ltd. 20 Rodborough Rd, Frenchs Forest NSW 208, Australia.
Aridol is distributed by Methapharm in the United States. Copyright © Methapharm Inc. 2022. All rights reserved.